Insider trade

Pfizer (PFE): Executive Vice President received 82K units

Lidia Fonseca, Executive Vice President at Pfizer, reported a grant / award of 82K units.

82K
Derivative units
Traded
Mar 3, 2026
Filed
Mar 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 17, 2025Congress · 1 personMembers of Congress: 2 purchases
  2. Dec 19, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  3. Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
  4. Jan 2, 2026Government · Federal Register noticeRevocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
  5. Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
  6. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
  7. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
  8. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  9. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
  10. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  11. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
  12. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  13. Feb 24, 2026FDAFDA drug approval: Braftovi
  14. Feb 24, 2026FDAFDA drug approval: Braftovi
  15. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH

What came next

  1. Mar 6, 2026FDAFDA drug approval: Xeljanz
  2. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
  3. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  4. Mar 13, 2026CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  5. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  6. Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
  7. Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
  8. Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  9. Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
  10. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  11. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  12. May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
  13. May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
  14. May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  15. Jun 5, 2026FDAFDA drug approval: Hympavzi
  16. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  17. Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
  18. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
  19. Jun 24, 2026FDAFDA drug approval: Ibrance
  20. Jun 24, 2026FDAFDA drug approval: Ibrance
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Explore the data

Common questions

Which Pfizer (PFE) insider traded, and how much?

Lidia Fonseca, Executive Vice President at Pfizer, reported a grant / award of 82K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Mar 3, 2026. Filed: Mar 5, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data